Fresenius Kabi Executive and Leadership Team

Pfizer is a biopharmaceutical company that researches, develops, manufactures, and markets medicines and vaccines across multiple therapeutic areas. The company focuses on areas such as oncology, internal medicine, inflammation and immunology, and vaccines to help prevent, treat, and manage disease worldwide.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Shionogi & Co., Ltd. is a Japanese pharmaceutical company dedicated to developing innovative treatments that improve patient lives worldwide. With a longstanding focus on addressing pressing global health challenges, the company has been a pioneer in discovering and delivering novel therapies for infectious diseases, including antibiotics, HIV, influenza, and emerging viral threats such as COVID-19. Shionogi combines in-house research and development with strategic collaborations across industry, government agencies, biotech companies, and academic institutions to accelerate the advancement of its scientific programs and bring meaningful therapies to patients with urgency and precision.

OneSource Specialty Pharma Limited is a multimodal specialty pharmaceutical contract development and manufacturing organization headquartered in Bengaluru, India. Formed through the merger of three CDMO businesses within the Strides Group, specifically Stelis Biopharma's Biologics CDMO, SteriScience's Complex Injectables, and Strides' Soft Gelatin businesses, OneSource was officially launched at CPHI Milan in 2024. The company operates five state-of-the-art manufacturing facilities in Bengaluru, all approved by major regulatory bodies including the US FDA, European Union authorities, and the Therapeutic Goods Administration. With over 30 years of manufacturing and quality excellence, OneSource employs more than 1,200 professionals, including over 200 techno-commercial experts, and serves more than 50 global pharmaceutical and biotechnology clients. The company specializes in end-to-end capabilities across multiple technology platforms and therapeutic modalities, including biologics drug substance and drug product manufacturing, drug-device combinations such as prefilled syringes and autoinjectors, complex sterile injectables, and soft gelatin capsules. OneSource has the capacity to produce over 100 million injectable doses and 2.4 billion soft gelatin capsules annually, with its flagship Bangalore site being one of the few facilities globally capable of manufacturing both biologics drug substance and drug product on the same premises. The company holds 35 approved Abbreviated New Drug Applications and has 19 commercialized drug products in the United States. Led by CEO Neeraj Sharma and Chief Quality Officer Bernhard Thurnbauer, OneSource is positioned to capitalize on growing demand for GLP-1 drug-device combinations and supply chain diversification driven by the BIOSECURE Act, projecting 32 percent revenue growth in 2025 with sales expected to reach 400 million dollars by 2028.